Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension

Conclusion: In China, adding selexipag may not be cost-effective for patients with PAH who failed to control their condition after combined treatment of ERA and PDE5i. Results of the analysis can aid discussions on the value and position of selexipag for the combined treatment of PAH.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research